Filing search / Fate Therapeutics, Inc. / "Benefits"

8-K

EX-99.1

FATE Fate Therapeutics, Inc.

5 Mar 25

Fate Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates

4:02pm

be observed during preclinical or clinical development), the risk that its product candidates may not produce therapeutic benefits or may cause other

8-K

FATE Fate Therapeutics, Inc.

6 Jan 25

Departure of Directors or Certain Officers

4:01pm

, until the earliest of (A) Mr. Wolchko’s eligibility for group health plan benefits under any other employer’s group health plan; or (B) the cessation

8-K

EX-10.1

FATE Fate Therapeutics, Inc.

6 Jan 25

Departure of Directors or Certain Officers

4:01pm

termination or expiration. 7. Relationship of the Parties; Independent Contractor; Employee Benefits. Advisor is an independent contractor

8-K

EX-99.1

6pstotkl30dnkm

29 Nov 24

Fate Therapeutics Announces Leadership Transition

2:33pm

8-K

EX-99.1

9r28gl

12 Nov 24

Fate Therapeutics Reports Third Quarter 2024 Financial Results and Business Updates

4:01pm

8-K

EX-10.1

jhkq6dv6ca0

30 Aug 24

Entry into a Material Definitive Agreement

4:21pm

8-K

EX-99.1

yph5ng9

13 Aug 24

Fate Therapeutics Reports Second Quarter 2024 Financial Results and Business Updates

4:06pm

8-K

EX-99.1

isdomsbnswm4bnw ss

31 Jul 24

Fate Therapeutics Appoints Neely Mozaffarian, MD, PhD, FACR, to its Board of Directors

4:03pm

8-K

EX-99.1

gjy2e6y

9 May 24

Fate Therapeutics Reports First Quarter 2024 Financial Results and Business Updates

4:02pm

8-K

EX-99.1

xkxm zuhb667yqp6std

9 May 24

Fate Therapeutics Announces First Lupus Patient Treated in Phase 1 Autoimmunity Study of Off-the-shelf FT819 CAR T-cell Program

9:01am

8-K

x16tgf

9 May 24

Fate Therapeutics Announces First Lupus Patient Treated in Phase 1 Autoimmunity Study of Off-the-shelf FT819 CAR T-cell Program

9:01am

424B3

wsib9t1 v86z5hu

2 May 24

Prospectus supplement

4:02pm